The Prognostic Significance of Selected HLA Alleles on Prostate Cancer Outcome.

Recently, we have shown that HLA-A02:01 and HLA-A24:02 in de novo metastatic prostate cancer (MPCa) have an important role in disease progression. Since de novo MPCa represents a small group among patients diagnosed with prostate cancer (PCa), it was obvious to try to extend the validity of our results to larger cohorts of PCa patients. Herein, we analyzed patients irrespective of their disease status at diagnosis to include, besides patients with MPCa, those with localized PCa (LPCa). Our goal was to specify the prognostic value of HLA-A02:01 and HLA-A24:02 for overall survival (OS) prospectively and for early biochemical recurrence (BCR) and castrate resistance (CR) as additional clinical endpoints in a prospective/retrospective manner, to improve clinical decisions for patients covering all stages of PCa. On univariate analysis, HLA-A alleles were significantly associated as prognostic biomarkers with early BCR ( = 0.028; HR = 1.822), OS ( = 0.013; HR = 1.547) and showed a trend for CR ( = 0.150; HR = 1.239). On multivariate analysis, HLA-A alleles proved to be independent prognosticators for early BCR ( = 0.017; HR = 2.008), CR ( = 0.005; HR = 1.615), and OS ( = 0.002; HR = 2.063). Kaplan-Meier analyses revealed that patients belonging to the HLA-A02:01HLA-A24:02 group progressed much faster to BCR and CR and had also shorter OS compared to HLA-A24:02 patients. Patients being HLA-A02:01HLA-A*24:02 exhibited varying clinical outcomes, pointing to the presence of additional HLA-A alleles with potential prognostic value. Our data underline the HLA-A alleles as valuable prognostic biomarkers for PCa that may assist with the appropriate treatment and follow-up schedule based on the risk for disease progression to avoid over-diagnosis and over-treatment.